Identifying factors that affect survival in Ewing Sarcoma patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to assess the correlation between various factors such as age, sex, tumor volume, tumor site, chemotherapy-induced necrosis, radiation, and biomarkers with overall survival and relapse-free survival in patients diagnosed with Ewing sarcoma. By reviewing clinical records of patients treated at the Rizzoli Orthopaedic Institute over a 30-year period, the study seeks to identify reliable prognostic factors that could help in stratifying patients based on their risk levels. This information may lead to tailored treatment approaches for high-risk patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Male and female patients treated at Rizzoli Orthopaedic Institute between 01/01/1991 and 31/12/2021
* Age ≥ 2 years
* Diagnosis of Ewing Sarcoma
* Patients with available clinical and imaging data

Exclusion Criteria:

* At least one inclusion criterion not met

Where it's running

• IRCCS Itituto Ortopedico Rizzoli
  Bologna, Bo, Italy Recruiting

Study contacts

• Study coordinator: Costantino Errani
• Email: costantino.errani@ior.it
• Phone: 0516366

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Dynamic ProGRP Changes During Ewing Sarcoma Treatment

  This study tests whether changes in serum ProGRP levels over time reflect how well newly diagnosed Ewing sarcoma responds to treatment.

  Recruiting Peking University People's Hospital · Beijing · NCT07725783

• Methionine-Reduced Diet in Solid Tumors (early-phase)

  A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.

  Recruiting Early Phase 1 University of California, Irvine · Orange, California · NCT07628634

• Adaptive Proton Therapy for Pediatric Solid Tumors and Hodgkin Lymphoma

  This study tests a regular imaging approach to see if proton therapy plans for children with solid tumors or Hodgkin lymphoma should be updated during treatment.

  Recruiting St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07514819

• Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma

  This trial tests whether adding eflornithine (DFMO) as extra or maintenance therapy can improve survival for young people with Ewing sarcoma or osteosarcoma.

  Recruiting at 3 sites Phase 2 Milton S. Hershey Medical Center · Tampa, Florida and 2 other locations · NCT07321912

• Xaluritamig for relapsed or refractory Ewing sarcoma in adults, adolescents, and children

  This trial will test xaluritamig in adults, adolescents, and children with relapsed or refractory Ewing sarcoma to find a recommended dose for expansion and check safety and tolerability.

  Recruiting at 13 sites Phase 1 Amgen · Los Angeles, California and 12 other locations · NCT07297979

• Hypofractionated radiation plus B7-H3 CAR T cells for children and young adults with relapsed sarcoma

  This will test whether short-course radiation given before B7-H3 CAR T-cell therapy is safe for children and young adults (≤21) with relapsed or refractory B7-H3–positive sarcomas.

  Recruiting Phase 1 St. Jude Children's Research Hospital · Memphis, Tennessee · NCT07222735

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.